Natures Sunshine Products Inc (NATR) valuation
Natures Sunshine Products P/E ratio history
Natures Sunshine Products trades at 12.1 times its earnings over the last twelve months and 10.6 times the earnings analysts expect over the next twelve. At its last 7 fiscal year ends its P/E ranged from 13.0 (year to Dec 2021) to 125.0 (year to Dec 2016), with a median of 22.5.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $21.58 | $1.06 | 20.4 | 20.8 |
| Dec 31, 2024 | $14.66 | $0.40 | 36.7 | 20.4 |
| Dec 31, 2023 | $17.29 | $0.77 | 22.5 | — |
| Dec 31, 2022 | $8.32 | -$0.02 | n/m | — |
| Dec 31, 2021 | $18.50 | $1.42 | 13.0 | — |
| Dec 31, 2020 | $14.95 | $1.07 | 14.0 | — |
| Dec 31, 2019 | $8.93 | $0.35 | 25.5 | — |
| Dec 31, 2018 | $8.15 | -$0.04 | n/m | — |
| Dec 31, 2017 | $11.55 | -$0.69 | n/m | — |
| Dec 31, 2016 | $15.00 | $0.12 | 125.0 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Natures Sunshine Products valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Natures Sunshine ProductsNATR | $215M | 12.1 | 10.6 | 0.4 |
| Nu Skin EnterprisesNUS | $226M | — | 4.7 | 0.2 |
| LimoneiraLMNR | $194M | — | 61.4 | 1.5 |
| B And G FoodsBGS | $188M | — | 4.3 | 0.1 |
| Niagen BioscienceNAGE | $186M | 12.9 | — | 1.4 |
| Usana Health SciencesUSNA | $264M | — | 11.2 | 0.3 |
| AlicoALCO | $277M | 178.1 | — | 16.2 |
| BrcBRCC | $314M | — | 51.5 | 0.7 |
| MedifastMED | $136M | — | — | 0.5 |
| Peer median | 95.5 | 11.2 | 0.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: NATR financials · NATR returns
No forecast, no recommendation. This page describes Natures Sunshine Products Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.